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ABSTRACT
With the advent of new oral anticoagulants
(NOACs) for the treatment of deep-vein
thrombosis (DVT) and/or pulmonary
embolism (PE), a new era of oral
anticoagulation for patients with venous
thromboembolism (VTE) has begun.
Rivaroxaban is the first NOAC to receive
regulatory approval for the acute and
continued treatment of DVT and PE, and for
the secondary prevention of VTE. Here, the
clinical trials of rivaroxaban in patients with
VTE are reviewed, and the clinical use of
rivaroxaban for patients with PE is discussed.
Even though rivaroxaban will facilitate the
therapeutic management of PE, its use in
specific clinical situations needs further study.
Keywords: Anticoagulation; Cardiology;
Deep-vein thrombosis; New oral anticoagulants;
Rivaroxaban; Pulmonary embolism; Venous
thromboembolism
INTRODUCTION
Deep-vein thrombosis (DVT) and pulmonary
embolism (PE) are two different clinical
manifestations of venous thromboembolism
(VTE) (incidence 1–1.5 per 1,000 person years)
[1]. PE is the third most common cause of
cardiovascular mortality, after acute coronary
syndromes and stroke [2]. The reported all-cause
mortality after acute PE is 5–15% [3], driven by
the severity of the initial presentation, recurrent
PE, and associated comorbidities.
In the treatment of VTE, three distinct
phases can be identified: initial treatment,
continued treatment, and long-term secondary
prevention of recurrent VTE [4, 5]. Although the
treatment of DVT and PE share the same
principles, the potentially life-threatening
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outcome of (recurrent) PE explains the
differences in the practical therapeutic
management of DVT and PE. Therapy for PE is
more rigorously monitored, and the increased
clinical vigilance in the initial treatment phase
explains the reluctance for ambulatory
treatment. Compared with DVT treatment,
there is also a lower threshold for long-term
secondary prevention after an unprovoked PE.
The perception that PE patients differ from
DVT patients is also illustrated by the different
time course in the implementation of
therapeutic innovations. The use of low
molecular weight heparins (LMWHs) was
investigated and implemented in DVT patients
before it became standard practice in PE
patients [6–8]. Likewise, whereas the
ambulatory treatment of patients with DVT
has been widespread for over a decade [9, 10],
outpatient treatment of patients with PE at low
risk of an adverse outcome has only been
validated in the past years [11]. Due to these
differences in outcome and nuances in
therapeutic approach, efficacy and safety
outcomes may not be readily translatable from
one group of VTE patients to another.
Conventional anticoagulant treatment
has certain well-known drawbacks, both
pharmacologically and practically.
Nonetheless, these drugs have been used for
decades, and physicians are well trained in the
use of LMWHs and vitamin K antagonists
(VKAs). Conversely, although new oral
anticoagulants (NOACs) offer a promising
potential to overcome these limitations
through their oral availability and more
predictable pharmacokinetics, it will require
some time to optimally implement their use in
clinical practice.
This manuscript aims to highlight the
evidence as well as the areas of uncertainty for
the use of rivaroxaban in the treatment of PE.
CLINICAL DEVELOPMENT
OF RIVAROXABAN
Rivaroxaban was the first drug to receive
regulatory approval for the treatment of VTE,
but it is expected that dabigatran, apixaban, and
edoxaban will also become available for this
indication, as these drugs are in their final phases
of their clinical development programmes or
regulatory approval [12–15].
Prevention of VTE After Major
Orthopaedic Surgery
All NOACs follow a similar pattern of clinical
development. Clinical trials in the prevention
of VTE after major orthopaedic surgery, using a
venogram to assess their efficacy in preventing
mostly asymptomatic venous thrombosis, are a
well-established clinical development model to
validate the efficacy and safety of NOACs. The
approval of NOACs for the prevention of VTE in
orthopaedic patients has preceded other
indications: dabigatran, rivaroxaban, apixaban,
and edoxaban all are approved in some parts of
the world for preventing VTE after elective knee
or hip replacement [16].
The RECORD programme (Regulation of
Coagulation in major Orthopaedic surgery
reducing the Risk of DVT and PE) investigated
rivaroxaban for the prevention of VTE after major
orthopaedic surgery. These trials demonstrated a
superior efficacy of rivaroxaban 10 mg once-daily
(od) as compared with subcutaneous enoxaparin
40 mg od or enoxaparin 30 mg twice-daily (bid)
for thromboprophylaxis after knee and hip
replacement surgery, without a clinically
significant excess of bleeding events [17–20].
The efficacy and safety of rivaroxaban was
further confirmed in post-marketing studies
and phase 2 studies with rivaroxaban as the
comparator drug [21, 22].
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Treatment of DVT and PE
Once trials have established the efficacy and
safety of NOACs in the prevention of VTE after
major orthopaedic surgery, large-scale trials are
initiated for the treatment and secondary
prevention of VTE, and for stroke prevention
in patients with atrial fibrillation. The EINSTEIN
programme investigated the efficacy and safety
of rivaroxaban for the treatment of acute DVT
(EINSTEIN DVT), acute PE (with or without
symptomatic DVT; EINSTEIN PE), and for the
secondary prevention of recurrent symptomatic
VTE (EINSTEIN-Extension) [23, 24]. An
overview of the design of these trials is shown
in Fig. 1 [23, 24].
The main efficacy and safety outcomes of the
EINSTEIN studies are summarized in Table 1
[23, 24].
Rivaroxaban was consistently shown to be
non-inferior to standard enoxaparin/VKA
therapy for the reduction of recurrent VTE in
EINSTEIN DVT and EINSTEIN PE. These trials
collectively included over 8,000 patients and
were statistically powered to investigate
outcomes in patients with DVT and PE.
However, some differences between the
results of the EINSTEIN DVT and EINSTEIN PE
studies are worth mentioning. In the DVT
study, there was a trend for a superior efficacy
outcome with rivaroxaban compared with
enoxaparin/VKA therapy [2.1 versus 3.0%,
respectively; hazard ratio (HR) = 0.68;
P = 0.08], which was not observed in the
EINSTEIN PE study (2.1 versus 1.8%; HR = 1.12;
P = 0.57) [23].
In EINSTEIN PE, a 50% reduction in major
bleeding was observed in patients receiving
Fig. 1 Design of the EINSTEIN DVT, EINSTEIN PE, and EINSTEIN-Extension trial. bid twice-daily, DVT deep-vein
thrombosis, INR international normalized ratio, od once-daily, PE pulmonary embolism



































































































































































































































































































































































































































































































































































































































































































































































































































































































592 Adv Ther (2013) 30:589–606
123
rivaroxaban as compared with those receiving
enoxaparin/VKA therapy (1.1 versus 2.2%,
respectively; HR = 0.49, P = 0.003). The
reduction in major bleeding with rivaroxaban
was only significant in EINSTEIN PE, whereas a
trend in the reduction of major bleeding was
observed in EINSTEIN DVT (0.8 versus 1.2%,
respectively; HR = 0.65; P = 0.21) [24].
Thus, it seems that DVT and PE patient
populations are slightly different, or are being
managed differently by physicians. The
somewhat better quality of anticoagulant
management in the EINSTEIN PE study [time
in therapeutic range (TTR): 63%] as compared
with the EINSTEIN DVT study (TTR: 58%), and
the longer anticoagulant treatment duration of
patients with PE as compared with patients with
DVT illustrate the more vigilant attitude of
physicians towards patients with PE, which
may, in part, explain the observed differences
in efficacy and safety outcomes of the EINSTEIN
studies.
INTERNAL VALIDITY
OF THE EINSTEIN STUDIES
Design
The EINSTEIN DVT and EINSTEIN PE studies
were open-label studies with a prospective,
randomized, open-label, blinded-endpoint
adjudication design (PROBE). The pros and
cons of open-label versus double-blind studies
with a VKA comparator have been discussed
extensively [25]. Double-blind trials imply the
use of a double dummy and a ‘shammed’
international normalized ratio (INR) when
warfarin is the active comparator. Hence, trial
logistics and feasibility are more challenging
and the clinical management of experienced
study centres may not reflect clinical reality. In
contrast, open-label studies are prone to bias.
This bias may go against the investigational
drug, as was suggested in the EINSTEIN studies,
with an increased diagnostic suspicion of
recurrent events in the rivaroxaban groups,
and an underreporting of bleeding outcomes
in the comparator group [23, 24]. This
underlines the need for a stringent reporting
of suspected outcomes, and a blinded,
independent adjudication committee.
Initial Treatment: Single-Drug, Dual-
Intensity Versus Dual-Drug Approach
In contrast with the delayed onset of the
anticoagulant effect of VKAs, NOACs have a
rapid onset of anticoagulant activity, similar to
LMWHs [26]. NOACs may, thus, provide timely
therapeutic anticoagulation when administered
as the initial treatment to patients with acute
VTE, obviating the need for an initial treatment
period with LMWHs.
Previous clinical development programmes
have pointed to the importance of the initial
treatment phase. The recurrent events in the
first month of ximelagatran treatment (single
drug/single intensity) when compared with
standard LMHW/VKA treatment suggested a
need for an intensified initial treatment [27].
This initial treatment phase may be especially
relevant in patients with PE. Indeed, the long-
acting factor Xa inhibitor, idraparinux, was less
effective than standard therapy in the initial
treatment of PE, whereas its efficacy was similar
to standard antithrombotic therapy for DVT
[28].
In the EINSTEIN studies, a single-drug
approach has been investigated with an
intensified regimen for 3 weeks [23, 24]. This
duration of intensified treatment was modelled
on dose-finding studies, which showed that a
strategy of 15 mg bid (for 3 weeks) followed by
20 mg od (for continued treatment) was not
Adv Ther (2013) 30:589–606 593
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associated with an increased risk of bleeding
when treating patients with acute symptomatic
DVT, and that it was effective, as suggested by a
reduction in thrombus burden, as a surrogate
endpoint for efficacy in these phase 2 trials
[29, 30].
The Apixaban after the Initial Management
of Pulmonary Embolism and Deep-Vein
Thrombosis with First-Line Therapy (AMPLIFY)
study, investigating apixaban for the treatment
of DVT and PE, also opted for a single-drug
approach. In this trial, however, the intensified
treatment was limited to 1 week of apixaban
10 mg bid, followed by apixaban 5 mg bid after
the first week [12].
In contrast, in the clinical trials with
dabigatran and edoxaban, the initial treatment
was open-label therapeutic unfractionated
heparin (UFH) or LMWH in both treatment
arms, overlapping with either warfarin or sham
warfarin [13, 15]. In these double-blind studies,
therapy was then continued with warfarin
or the NOAC under investigation upon
discontinuation of the open-label UFH/
LMWH, i.e. when the (sham) INR is in
therapeutic range. This dual-drug approach
raises the question of which duration of initial
LMWH treatment prior to starting the NOAC is
needed in clinical practice.
Since no phase 2 studies had been carried out
with rivaroxaban in patients with PE, the
EINSTEIN PE study included a repeat imaging
scan after 3 weeks of treatment in the first 400
patients who were randomized in the EINSTEIN
PE study. The clot resolution was similar in
rivaroxaban and enoxaparin/VKA patients.
Remarkably, 3 weeks of anticoagulant
treatment resulted in a decrease of vascular
obstruction of 71 and 62%, and a complete clot
resolution in 44 and 31% when analysed with
computed tomography (CT) scan and perfusion
scanning, respectively [31].
Non-Inferiority Analysis
The primary efficacy analysis was a non-
inferiority analysis, with a non-inferiority
margin of 2.0 [24]. The non-inferiority margin
of 2.0 may appear a generous margin of non-
inferiority, as apparently, a non-inferiority claim
could be granted despite twice as many recurrent
events. However, the non-inferiority claim
implied that the upper limit of the 95%
confidence interval (CI) for the HR of the
primary efficacy outcome was less than this pre-
specified margin of 2.0. Since the upper limit of
the 95% CI was indeed lower than 2.0 (HR = 1.12,
95% CI 0.75, 1.68), the trial demonstrated non-
inferiority. The statistical concept of the non-
inferiority margin in the EINSTEIN studies was
based on preserving at least 75% of the treatment
effect of the comparator arm.
For clinicians, this statistical concept is best
translated into absolute rates or recurrences.
The observed absolute difference for the patient
population with PE included in the EINSTEIN
PE study was 0.24% (95% CI -0.5, 1.0%); thus,
excluding an absolute of 1% of the primary
efficacy outcome recurrent VTE.
EXTERNAL VALIDITY
OF THE EINSTEIN PE STUDY:
IMPLICATIONS FOR PHYSICIANS
AND PATIENTS
The patient management and the patient
characteristics in clinical studies are different
from daily clinical practice [32]. Even if an
open-label clinical trial, such as the EINSTEIN
PE study, more closely resembles clinical
practice than a double-blind clinical study
with a VKA, the patient selection and the
meticulous follow-up of clinical trial patients
are likely to lead to superior anticoagulant
control.
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This raises a number of questions: to which
extent does the EINSTEIN PE study allow
physicians to evaluate and implement this
new treatment in a wide range of patients?
Can we identify patients who are most likely to
benefit? And which PE patients are not good
candidates for oral rivaroxaban? Here, the
authors discuss the clinical path of a patient
with PE, from clinical suspicion to long-term
secondary prevention, with a focus on the
potential impact of this new therapy.
Impact on Diagnosis
The diagnostic algorithms, combining clinical
probability (empirical or using prediction
scores), D-dimer level and widely available
imaging techniques (CT angiography having
largely replaced ventilation–perfusion lung
scintigraphy) have facilitated the diagnostic
strategies [33, 34]. Nevertheless, in patients
with a suspected diagnosis of PE, decisions
about empirical treatment are often made
prior to a definite diagnosis. In patients with a
high clinical probability without an elevated
bleeding risk, anticoagulant treatment with
heparins can be initiated prior to objective
diagnosing PE [33, 35, 36].
Whereas rivaroxaban may be an alternative
for LMWH in case of suspected DVT, awaiting
the ultrasound result to objectively confirm or
refute the diagnosis, physicians are more
reluctant to initiate oral rivaroxaban prior to
the diagnostic investigations for suspected PE.
Indeed, the alternative diagnoses and the
potential interventions in patients who
present with an acute chest syndrome and the
absence of an antidote (should an invasive
procedure be needed or in case of a bleeding)
justify a more conservative approach for
patients with a high clinical probability of PE,
who are often hospitalized as opposed to the
more ambulatory setting of patients with
suspected DVT. Therefore, patients with a high
clinical probability of PE for whom initiating
anticoagulant treatment prior to the diagnostic
exams is considered appropriate are better
initiated on LMWH or UFH.
Impact on Initial Treatment of Patients
with PE
High-Risk Patients
Patients with PE or with a high probability for
PE should be stratified based on their risk
profile. The PE-related early mortality of high-
risk patients, i.e. patients who are
hemodynamically unstable, is high ([15%)
[33, 37]. Unstable patients presenting with
shock or hypotension should be treated with
thrombolytic therapy, or considered for
embolectomy if thrombolysis is contra-
indicated [38]. Patients with hemodynamic
instability and patients who received
thrombolytic therapy were not included in
NOAC trials (Fig. 1). These patients can,
therefore, not be considered appropriate
candidates for initial treatment with
rivaroxaban. However, upon favourable
clinical evolution, rivaroxaban can be
considered for the continued treatment and
for long-term secondary prevention.
Intermediate-Risk Patients
Intermediate-risk patients can be identified
based on the presence of right ventricular (RV)
dysfunction (RV dilatation on
echocardiography or CT scan, increased levels
of natriuretic peptides) or markers of
myocardial injury (cardiac troponins) [33].
Patients with so-called ‘submassive’ PE
associated with RV dysfunction and/or
increased cardiac biomarkers should be
Adv Ther (2013) 30:589–606 595
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monitored closely, and thrombolytic therapy
should be considered upon unfavourable
clinical evolution after the initiation of
anticoagulant therapy [35]. It seems cautious
to administer parenteral heparin to patients
who might be candidates for thrombolytic
therapy [35].
A limitation of the EINSTEIN PE study [24] is
the absence of markers of PE severity or data on
RV dysfunction or damage in the EINSTEIN PE
study. However, the EINSTEIN PE study does
include indirect markers of PE severity (i.e. the
stay in intensive care units in 12% of included
patients), or the demonstration of extensive
disease based on the anatomical extent of the
thrombus load, as assessed on CT scan or
perfusion scintigraphy, to illustrate that a
significant portion of the included patients
had extensive disease [24].
Most physicians will delay the intake of an
oral drug until the initial clinical evolution is
favourable and the patient remains stable. For
the majority of the patients, close monitoring of
1–2 days is adequate to confirm a reassuring
clinical evolution, after which oral treatment
can be initiated.
Low-Risk Patients
The majority of patients included in the
EINSTEIN PE study were low-risk patients. Of
note, 58 and 33% of patients who were
randomized in the EINSTEIN PE study were
pretreated with LMWH for 1 or 2 days prior to
randomization, respectively [24]. This means
that \10% of all study patients were treated
with a strictly one-drug regimen. However,
given the rapid onset of action of NOACs and
the consistent finding of non-inferiority
throughout the study, it seems fair to assume
that an all-oral regimen from the start is
suited for most patients in the absence of
elevated risk.
Will NOACs Facilitate Outpatient Treatment
of Low-Risk Patients?
For low-risk patients, outpatient treatment has
recently been validated as a safe alternative for
hospitalization [11]. The EINSTEIN PE study
recruited mainly a lower-risk population, which
is illustrated by the rather low overall mortality
rate during the intended treatment period
(2.5%) [24]. The EINSTEIN PE study reported
that 89% of patients were hospitalized,
suggesting that a fair minority of
approximately 10% were not hospitalized, or
observed for \24 h [24]. The single-drug
approach, without the need for subcutaneous
injections nor frequent INR measurements, will
further facilitate ambulatory treatment in low-
risk patients, but validation of the safety and
efficacy of ambulatory treatment of low-risk PE
patients with a NOAC would be welcomed.
Several clinical prognostic scores for PE have
been validated to help physicians identify low-
risk patients with a PE who are potential
candidates for outpatient care, such as the
(simplified) Pulmonary Embolism Severity
Index (PESI) [39–41]. Unfortunately, these
scores were not determined in the EINSTEIN
PE study.
Impact on Continued Treatment
and Follow-Up of Patients
VKAs, with a target INR of 2–3, are the gold
standard for continued treatment and long-
term secondary prevention. In case of
rivaroxaban treatment, the initial treatment
phase encompasses an intensified treatment
regimen (15 mg bid) for 3 weeks, followed by
continued treatment of 20 mg od for at least
3 months (Fig. 2).
The stringent need for INR monitoring and
dose adjustment of VKAs ensured a clinical
follow-up of patients with acute PE. The absence
596 Adv Ther (2013) 30:589–606
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of routine laboratory monitoring is an
advantage, but does not alleviate the need for
patient education and a clinical follow-up.
Furthermore, the absence of laboratory
monitoring could potentially impact on the
compliance, which is of the utmost importance
in the initial weeks after an acute PE. Indeed,
because of their short therapeutic half-life [42],
compliance is even more crucial for NOACs, as a
treatment interruption as short as a single day
will leave the patient without anticoagulant
protection. Thus, it seems cautious to shift from
routine coagulation monitoring to a clinical
path with a follow-up after 3–4 weeks (verifying
the appropriate dose change and treatment
adherence), after 3 and 6 months, and later on
tailored to the individual patient profile.
Impact on Duration of Treatment
All patients with PE should continue
anticoagulant treatment for at least 3 months.
Anticoagulant treatment can be discontinued
after 3 months in patients with a provoked PE
secondary to a transient risk factor. In clinical
practice, physicians are often inclined to
Fig. 2 Overview of different treatment strategies for the
initial and continued treatment of acute VTE, and for the
long-term secondary prevention of VTE. bid twice-daily,
INR international normalized ratio, LMWH low-molecular
weight heparin, od once-daily, Pgp P-glycoprotein, VTE
venous thromboembolism, atrial results not yet published,
bdose reduction to 30mg od in patients with body weight
\60 kg, patients with a creatinine clearance between 30–50
mL/min, and patients with concomitant use of Pgp
inhibitors
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prolong this treatment phase and prescribe at
least a 6-month course of anticoagulation in PE
patients. This is also reflected in the EINSTEIN
PE study, where the intended treatment
duration was 3 months in only 5% of patients
[24], versus 12% of patients in the EINSTEIN
DVT study [23].
Patients with unprovoked PE or permanent
risk factors need to be considered for long-term
secondary prevention, taking into account the
risk of recurrence, the bleeding risk, and the
patient’s preferences [33, 35].
The efficacy and safety results of the
EINSTEIN PE and EINSTEIN-Extension study,
and the more convenient treatment with
rivaroxaban or any other approved NOAC will
likely impact on the clinical decision to stop or
continue anticoagulation treatment, e.g. in
patients in whom difficulties related to VKA
management drive the decision to stop
anticoagulation despite a high risk of recurrent
VTE. Anticoagulant therapy is also frequently
discontinued in patients with bleeding
complications, or patients considered at an
increased risk for bleeding. The lower
incidence of major bleedings observed with
rivaroxaban in the EINSTEIN PE study may
lower the threshold for continuing secondary
VTE prevention in these patients. The use of
bleeding risk scores [43] and more real-life data
on the benefit-to-risk profile of NOACs in
patients at increased risk of bleeding are
needed. An individualized approach for
treatment duration and a periodic benefit/risk
evaluation remains essential.
Although the results of the EINSTEIN-
Extension trial showed a clear reduction in
VTE recurrence in patients treated with
rivaroxaban versus untreated patients [44],
long-term treatment with rivaroxaban was not
compared with long-term VKA treatment.
Whereas it seems plausible to assume that the
efficacy and safety compared to VKA treatment
in the acute treatment studies can be extended
to prolonged treatment, long-term registries are
needed to investigate this assumption.
Furthermore, it is of interest that patients with
a clear indication for long-term anticoagulant
treatment were excluded from the EINSTEIN-
Extension trial, and only 5% of patients in the
acute treatment trials had a known
prothrombotic condition [23, 24]. Patients
with a high risk of VTE recurrence may, thus,
be underrepresented in the EINSTEIN
programme.
Optimal Dose for Long-Term Secondary
Prevention?
Based on the EINSTEIN studies and the
pharmacokinetic profile of rivaroxaban, the
current summary of product characteristics
(SmPC) of rivaroxaban stipulates a fixed dose
of 20 mg for both the continued treatment and
secondary prevention of recurrent VTE,
suggesting, however, to consider a dose
reduction to 15 mg in patients at high risk of
bleeding [42]. The AMPLIFY-extend study has
shown that lowering the dose of apixaban for
long-term secondary prevention (2.5 mg bid
rather than 5 mg bid) improved the benefit-to-
risk profile of apixaban, i.e. assured effective
prevention of recurrent VTE with a reduced
incidence of bleeding complications [12]
(Fig. 2).
Hence, also in view of the efficacy of
rivaroxaban 10 mg od in the primary
prevention of VTE after major orthopaedic
surgery [18–20], it is a valid and yet
unanswered question whether a dose
reduction of rivaroxaban should be considered
for long-term secondary prevention, especially
for frailer patients or patients at increased
bleeding risk.
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It is of interest that in the Multicenter,
Randomized, Parallel-Group Efficacy and
Safety Study for the Prevention of Venous
Thromboembolism in Hospitalized Acutely Ill
Medical Patients Comparing Rivaroxaban with
Enoxoparin (MAGELLAN) trial, some bleeding
complications were identified with a 10 mg
dose of rivaroxaban in acutely ill medical
patients [45]. Additional studies are needed to
address whether the prolonged use of
‘therapeutic’ doses of rivaroxaban may lead to
an excess of bleeding in the long term,
especially in patients with a fluctuating health
status.
Impact on the Management of Specific
Patient Populations
Patients with special characteristics were often
excluded from participation in the EINSTEIN
studies and may be unfit for NOAC treatment.
Pregnancy and Breastfeeding
Rivaroxaban is contra-indicated in patients who
are pregnant or who are breastfeeding [42]. For
female patients on long-term anticoagulant
treatment who wish to become pregnant,
VKAs are recommended, which should be
switched to LMWHs prior to the sixth week of
pregnancy [46].
Cancer
PE is a significant cause of morbidity and
mortality in patients with most types and
stages of cancer [47, 48]. Treatment with VKAs
can be complex, due to chemotherapy-related
complications, such as drug interactions,
nausea, or thrombocytopenia, or the
interruption of therapy because of invasive
procedures [35]. LMWHs are currently the
agents of choice for both acute and continued
treatment of VTE in patients with cancer.
Clinical data on NOACs are limited; only a
small proportion of patients with cancer were
included in the EINSTEIN studies
(approximately 5–7%) [23, 24, 49]. A clinical
trial comparing rivaroxaban (or another NOAC)
with LMWHs in patients with cancer would be
welcomed.
Elderly Patients
Elderly patients are at increased risk of both
recurrent VTE and bleeding. Furthermore,
elderly patients are typically underrepresented
in clinical trials, and the patients of advanced
age who are included in clinical trials are often
less frail compared with typical geriatric
patients who present with comorbidity and
multiple concomitant medications. In general,
clinical trial results should be transposed to
elderly patients with caution.
The mean age of the EINSTEIN PE patient
was approximately 58 years. However, the
reduction in major bleeding in the EINSTEIN
PE study was also observed in elderly patients
[24, 50]. In addition, in the EINSTEIN DVT
study, the net clinical benefit of rivaroxaban
was largest in frail patients [aged[75 years, with
body weight \50 kg or creatinine clearance
(CrCl) \50 mL/min] and elderly patients [23].
In a pooled data analysis from both EINSTEIN
DVT and EINSTEIN PE, the efficacy was
maintained in all different age subgroups [50].
However, this does not exclude that in this
higher risk, frail population, a reduced dose
could further improve the benefit-to-risk
profile.
Patients with Extreme Body Weight
Patients with extreme body weight, both very
low and very high, are underrepresented in
clinical trials and in preclinical dose-finding
studies. As rivaroxaban is given as a single dose
independent of therapeutic monitoring or of
Adv Ther (2013) 30:589–606 599
123
body weight, caution is needed in patients with
extreme body weight. It is of note that obese
patients seem to be reasonably well represented
in the EINSTEIN PE study, as 15% of the
patients had a body weight [100 kg, without
any concern for increased risk of recurrence
[24]. However, for patients with extreme body
weight, the authors would recommend VKAs or
an intermittent monitoring of anti-Xa activity.
Patients on Chronic Antiplatelet Treatment
The concomitant use of anticoagulant and
antiplatelet treatment increases the risk of
bleeding, and the optimal ‘cocktail’ of
anticoagulant and antiplatelet therapy in
patients with an indication for both remains
unknown.
Whereas VKAs have been validated both for
the secondary prevention of atherothrombotic
events and recurrent VTE [51], the efficacy of
NOACs for the secondary prevention of
atherothrombosis is yet to be established. On the
other hand, antiplatelet therapy also has a limited
effect on preventing recurrent VTE [52, 53].
Although not formally considered an
exclusion criterion, the concomitant use of
antiplatelet agents was discouraged for
patients in the EINSTEIN trials, and limited to
low-dose aspirin, low-dose clopidogrel, or both.
However, safety data in patients taking
concomitant antiplatelet drugs have not been
separately reported [24].
The Anti-Xa Therapy to Lower
Cardiovascular Events in Addition to Standard
Therapy in Subjects with Acute Coronary
Syndrome—Thrombolysis in Myocardial
Infarction-51 (ATLAS ACS 2—TIMI 51) trial
studied the effect of low-dose rivaroxaban on
top of dual antiplatelet treatment in patients
with recent acute coronary syndromes. While
low-dose rivaroxaban (2.5 mg bid or 5 mg bid)
successfully reduced recurrent ischemic events,
it was at the price of increased bleeding [54].
Notably, the apixaban for Prevention of Acute
Ischemic Events (APPRAISE) trial, comparing a
standard dose of apixaban (5 mg bid) versus
placebo on top of antiplatelet treatment of acute
coronary syndromes was halted early due to an
increased bleeding rate exceeding the reduction
in ischemic events [55]. While these trials report
on a very different patient population than PE
patients, they illustrate the importance of the
balance between anticoagulant and antiplatelet
treatment.
In conclusion, the combined use of
anticoagulant and antiplatelet agents should be
avoided whenever possible, and a critical
appraisal of the indication for either treatment is
needed. If the combination cannot be avoided,
reducing the dose or limiting the duration of
anticoagulant therapy seems prudent.
Patients with Reduced Renal Function
In the EINSTEIN studies, patients with a CrCL
\30 mL/min (based on the Cockroft–Gault
formula) were excluded from participation.
However, based on the results and the
pharmacokinetic profile, the current approval
for rivaroxaban includes patients with moderate
(CrCL 30–50 mL/min) and severe (CrCl
15–30 mL/min) renal impairment, without
dose reduction [42]. Because of the increased
drug levels in patients with severe renal
impairment, caution is indicated. The authors
would be inclined to propose a dose reduction
in patients with severe chronic impairment, and
in patients with moderate renal impairment
who have additional bleeding risk factors. The
potential value of monitoring drug levels or
coagulation tests is yet unclear.
Patients with Liver Disease
Patients with significant liver disease were also
excluded from the clinical trials of NOACs. It
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seems cautious not to use NOACs in patients
with liver disease associated with coagulopathy.
In contrast to the hepatotoxicity associated
with ximelagatran [27], there are currently no
known concerns with respect to liver
dysfunction for apixaban, rivaroxaban,
edoxaban, or dabigatran.
Patients with Known Prothrombotic
Conditions
No specific trials have investigated the efficacy
of NOACs in relation to genetic or acquired
thrombophilia, even though there is currently
no evidence that the presence of a
prothrombotic state impacts on either the
safety or the efficacy of the NOAC. Clinical
data of VTE treatment in patients with
hypercoagulability are lacking; but there is no
evidence that these patients should be treated
differently [56]. NOACs may lower the
threshold for continuing anticoagulant
treatment in patients with thrombophilia, but
this requires further study.
Pharmacokinetic Interactions
A list of drugs with potential interactions is
given in Table 2 [42]. The use of strong
P-glycoprotein (Pgp) inhibitors or certain drugs
interfering with cytochrome P450 3A5
(CYP3A4) were exclusion criteria in the
EINSTEIN programme. The concomitant use of
these drugs with rivaroxaban is not
recommended; however, no official
recommendation for dose reductions is given
[42]. In patients with atrial fibrillation, recently
published guidelines from the European Heart
Rhythm recommends to consider a dose
reduction of rivaroxaban in patients treated
with a CYP3A4- or Pgp-inhibitor who have
additional bleeding risk factors, such as
advanced age, reduced renal function, use of
antiplatelet agents, or a known bleeding
tendency. However, it should be noted that
patients with atrial fibrillation constitute a
different population [57].
Although pharmacologically relevant drug
interactions are much more frequent and often
less predictable with VKAs, the effect of drugs
on the anticoagulant effect of VKAs can easily
be assessed via monitoring of the INR.
Although the obviation of the need for
routine monitoring is welcome both from
practical and from health care expenditure
perspective, the availability of a reliable
coagulation assay can be of help to estimate
the intensity of anticoagulation in specific
situations, such as potential drug–drug
interactions, reduced hepatic and/or renal
function, and elderly patients.
DISCUSSION
Over the past decade, the availability of well-
validated clinical probability scores, D-dimer
assays, and the advances in pulmonary CT
angiography have facilitated the diagnostic
management of patients with suspected PE.
The approval of a new generation of orally
available anticoagulants for the treatment of
VTE will provide the clinician with a range of
convenient treatment options (Fig. 2).
In recent years, several large-scale landmark
trials of rivaroxaban as well as other NOACs in
the treatment of VTE have been published,
demonstrating their efficacy and safety in the
studied populations. However, the translation
of clinical trial results to clinical practice will
generate new questions.
Currently, rivaroxaban is the only NOAC
approved by the European Medicines Agency
(EMA) and the United States Food and Drug
Administration (FDA) for the treatment and
secondary prevention of DVT and PE. Although
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a comparison of the different clinical
development programmes and the results of
these studies are beyond the scope of this
manuscript, the differences in clinical trial
design have important implications, as they
lead to different initial treatment strategies
Table 2 Overview of drugs with relevant pharmacodynamic or pharmacokinetic interactions
Drug Mechanism of interaction SmPC
recommendationa
Major increase in plasma levels ([2-fold)
Azole antimycotics besides ﬂuconazole (ketoconazole,
itraconazole, voriconazole, posaconazole)
Pgp competition and strong CYP3A4
inhibition
Not recommended
HIV protease inhibitors (ritonavir) Pgp competition and strong CYP3A4
inhibition
Not recommended
Increase in plasma levels (\2-fold)
Quinidine Pgp competition No recommendation
Cyclosporin, tacrolimus Pgp competition No recommendation
Fluconazole Moderate CYP3A4 inhibition No clinically
signiﬁcant interaction








Possible increased plasma levels (no data available)




Decrease in plasma levels
Rifampicin Strong CYP3A4 inducer Use with caution
Phenytoin, carbamazepine, phenobarbital Strong CYP3A4 inducer Use with caution
St. John’s wort Strong CYP3A4 inducer Use with caution
Pharmacodynamic interaction
Antiplatelet drugs, NSAID Impaired hemostasis Use with caution
Warfarin Additive effect on anticoagulation, no
pharmacokinetic interaction
Use with cautionc
Other anticoagulants Additive effect on coagulation Use with caution
CYP3A4 cytochrome P3A4, ESC European Society of Cardiology, NSAID non-steroidal anti-inﬂammatory drug, Pgp
P-glycoprotein, SmPC summary of product characteristics
a Based on rivaroxaban summary of product characteristics (SmPC)-EU version, November 2012 [42]
b Amiodarone is not considered a contraindication in patients with normal-to-mildly reduced kidney function
c As rivaroxaban may increase the INR, in order to monitor the pharmacodynamic effect of warfarin, INR should be
measured at trough levels (24 h after the last dose of rivaroxaban) for minimal interference. Anti-Xa assays are not affected
by warfarin and can be used to monitor the pharmacodynamic effect of rivaroxaban
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depending on the NOAC of choice (as
summarized in Fig. 2).
Clinical trials mainly include a selected
patient population with lower-risk patients.
Although patients with comorbidities, frailty,
and concomitant medications were also
included in these trials, real-life experience
will need to accumulate in order to better
delineate candidates for treatment with the
different available NOACs.
Although only a small fraction of patients
from EINSTEIN PE was treated entirely with
rivaroxaban from the first treatment dose, the
efficacy and safety findings are most likely
extendable to a rivaroxaban-only treatment in
low-risk patients. While it, thus, seems
reasonable to start rivaroxaban as a single-drug
treatment in most hemodynamically stable
patients presenting with PE, current evidence
does not support a role for rivaroxaban in the
initial treatment of high-risk patients with
massive PE. In high- and intermediate-risk
patients, especially in patients in whom
thrombolysis is still considered a possible
treatment strategy, oral rivaroxaban should be
withheld until improvement of the patient’s
clinical condition. Rivaroxaban is also
inappropriate for the treatment of PE in
pregnant patients, or in patients with
significant hepatic or end-stage renal disease.
Although there is currently no evidence that the
efficacy and safety of rivaroxaban treatment is
different in cancer patients or in patients with
genetic or acquired prothrombotic conditions,
future studies need to better delineate the role of
NOACs in these patients.
Frail patients may potentially benefit from
the more stable pharmacodynamics of NOACs,
as suggested in a subanalysis showing that the
largest absolute clinical benefit was obtained in
elderly patients. However, it seems cautious to
organize a careful follow-up of renal function,
concomitant medication, and a frequent re-
assessment of other factors contributing to an
increased bleeding risk.
CONCLUSION
In conclusion, the development and approval of
rivaroxaban represent a true paradigm shift in
the management of patients with VTE. While
the EINSTEIN programme supports the use of
rivaroxaban as an attractive first-line treatment
in many PE patients, current evidence is still
insufficient to recommend rivaroxaban in
specific subpopulations.
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